First Patient Treated in Phase 1b/2 Pancreatic Cancer Trial with AIM's Ampligen® and AstraZeneca's Imfinzi®

AIM ImmunoTech Inc., a biopharmaceutical firm listed on the NYSE American, has initiated a Phase 1b/2 clinical trial at Erasmus Medical Center for patients with advanced pancreatic cancer. The study, known as DURIPANC, combines the company's drug Ampligen® (rintatolimod) with Imfinzi® (durvalumab), an anti-PD-L1 immune checkpoint inhibitor from AstraZeneca, to explore the potential of this combination in treating the disease.
The primary goal of the Phase 1b is to assess the safety of the combined therapy, while the Phase 2 aims to evaluate its clinical efficacy. Prof. Casper H.J. van Eijck, a pancreatic surgeon at Erasmus MC, is optimistic about the trial's potential to improve outcomes for patients with metastatic pancreatic cancer and anticipates completing the initial phase within six months.
The trial plans to enroll a total of up to 43 participants. Treatment will begin with Ampligen administered intravenously at a dose of 200 mg twice weekly for six weeks, with the option to escalate to 400 mg. Following this, durvalumab will be introduced at a dose of 1500 mg every four weeks for a possible 48 weeks, subject to disease progression and tolerability.
AIM ImmunoTech specializes in developing therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. Their flagship product, Ampligen, is a dsRNA and TLR3 agonist with demonstrated activity against various cancers and diseases in clinical trials.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!